CABALETTA BIO, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CABALETTA BIO, INC. (CABA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $4.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was -$795.00K, a 19975.00% decline year-over-year.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $4.84M, a 67.58% decline year-over-year.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $3.42M, a 68.84% decline year-over-year.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $2.72M.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $21.07M, a 92.20% increase from fiscal 2024.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $10.96M, a 435.30% increase from fiscal 2023.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.05M, a 85.09% decline from fiscal 2022.
- CABALETTA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $13.74M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$795.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.05M 10-Q · filed 2026-08-13 | $7.46M derived: sum of 3 quarters · filed 2026-08-13 | $10.18M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $4.84M 10-Q · filed 2026-05-14 | $8.26M derived: sum of 2 quarters · filed 2026-05-14 | $10.98M derived: sum of 3 quarters · filed 2026-05-14 | $10.98M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $6.14M derived: sum of 2 quarters · filed 2026-03-23 | $6.14M derived: sum of 3 quarters · filed 2026-08-13 | $21.07M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.73M derived: sum of 2 quarters · filed 2026-08-13 | $17.66M 10-Q · filed 2025-11-10 | $28.62M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $14.93M 10-Q · filed 2026-08-13 | $25.90M derived: sum of 3 quarters · filed 2026-08-13 | $25.90M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $14.93M 10-Q · filed 2026-05-14 | $25.89M derived: sum of 2 quarters · filed 2026-05-14 | $25.89M derived: sum of 3 quarters · filed 2026-05-14 | $25.89M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $10.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $10.96M derived: sum of 2 quarters · filed 2026-03-23 | $10.96M derived: sum of 3 quarters · filed 2026-03-23 | $10.96M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $13.53M 10-Q · filed 2024-11-14 | $1.49M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $4.21M 10-Q · filed 2024-08-08 | $1.49M derived: sum of 3 quarters · filed 2025-08-07 | $2.05M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $4.21M 10-Q · filed 2024-05-15 | $1.49M derived: sum of 2 quarters · filed 2025-05-15 | $2.05M derived: sum of 3 quarters · filed 2025-05-15 | $2.05M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.05M derived: sum of 2 quarters · filed 2025-03-31 | $2.05M derived: sum of 3 quarters · filed 2025-03-31 | $2.05M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $554.00K derived: sum of 2 quarters · filed 2024-11-14 | $554.00K 10-Q · filed 2024-11-14 | $14.29M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $13.74M derived: sum of 3 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | $13.74M derived: sum of 2 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | $13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $13.74M 10-K · filed 2024-03-21 | |||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | ||||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |